A clinical trial can be sponsored by an industry (company) or non-industry (government, individual/investigator-initiated, or institution).
Figure one: Non-industry-sponsored clinical trials by year. Credit: GlobalData.
When looking at non-industry-sponsored clinical trials since 2017, there has been a steady increase, from 32.1% of all clinical trials that year to 34.5% in 2019. This can be seen in figure one.
An analysis can be completed for those non-industry-sponsored clinical trials in 2019 by using the clinical trials database of GlobalData’s Pharma Intelligence Centre. In this article, a small number of phase zero, phase one / two, phase two / three and phase three / four trials were combined with phase one, phase two, phase three and phase four trials, respectively.
Figure two: 2019 non-industry-sponsored clinical trials by phase. Credit: GlobalData.
When looking at non-industry-sponsored clinical trials in 2019 in the database, it can be seen that phase two clinical trials outnumbered all other phases. Phase two clinical trials made up 49.7% of all clinical trials in 2019, with phase four following with 19.4%, phase one next with 16.4% and phase three with 14.5%. This can be seen in figure two.
Figure three: 2019 non-industry-sponsored clinical trials by therapy area. Credit: GlobalData.
Lastly, oncology was the top therapy area for non-industry sponsored clinical trials in 2019, as can be seen in figure three. They made up 25.7% of all clinical trials. The central nervous system (CNS) was second with 23.5%, followed by cardiovascular (8.9%), infectious disease (8.5%) and metabolic disorders (7.4%). Oncology, CNS, cardiovascular and infectious disease clinical trials all showed an increase in 2019 from 2018.